Skip to content
OpenCapital
Get started

ADMA Biologics ADMA Payments to Acquire Intangible Assets

Payments to Acquire Intangible Assets at other companies

Zymeworks logo
ZymeworksZYME
$0-100%

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S4×-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's payments to acquire intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's payments to acquire intangible assets?
ADMA Biologics (ADMA) reported payments to acquire intangible assets of $53K in Q1 2026.
How has ADMA Biologics's payments to acquire intangible assets changed year-over-year?
ADMA Biologics's payments to acquire intangible assets increased by 178.9% year-over-year, from $19K to $53K.
What does payments to acquire intangible assets mean?
Represents cash spent to acquire non-physical assets such as patents, licenses, or intellectual property. This is a key indicator of a company's commitment to long-term innovation and competitive positioning through strategic asset acquisition.